- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- AJANTA PHARMA - AUROBINDO PHARMA
AJANTA PHARMA vs AUROBINDO PHARMA - Comparison Results
Current Valuations
| AJANTA PHARMA | AUROBINDO PHARMA | AJANTA PHARMA/ AUROBINDO PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 21.8 | 19.3 | 113.0% | View Chart |
| P/BV | x | 5.1 | 4.8 | 105.5% | View Chart |
| Dividend Yield | % | 0.0 | 0.3 | - |
Financials
 AJANTA PHARMA  AUROBINDO PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| AJANTA PHARMA Mar-18 |
AUROBINDO PHARMA Mar-17 |
AJANTA PHARMA/ AUROBINDO PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,818 | 895 | 203.1% | |
| Low | Rs | 1,106 | 622 | 177.8% | |
| Sales per share (Unadj.) | Rs | 239.5 | 254.6 | 94.1% | |
| Earnings per share (Unadj.) | Rs | 52.8 | 39.3 | 134.4% | |
| Cash flow per share (Unadj.) | Rs | 59.5 | 46.6 | 127.8% | |
| Dividends per share (Unadj.) | Rs | 0 | 2.50 | 0.0% | |
| Dividend yield (eoy) | % | 0 | 0.3 | 0.0% | |
| Book value per share (Unadj.) | Rs | 230.0 | 160.0 | 143.8% | |
| Shares outstanding (eoy) | m | 88.77 | 585.88 | 15.2% | |
| Bonus/Rights/Conversions | - | ESOP | - | ||
| Price / Sales ratio | x | 6.1 | 3.0 | 204.9% | |
| Avg P/E ratio | x | 27.7 | 19.3 | 143.4% | |
| P/CF ratio (eoy) | x | 24.6 | 16.3 | 150.9% | |
| Price / Book Value ratio | x | 6.4 | 4.7 | 134.1% | |
| Dividend payout | % | 0 | 6.4 | 0.0% | |
| Avg Mkt Cap | Rs m | 129,782 | 444,390 | 29.2% | |
| No. of employees | `000 | 6.8 | 14.0 | 48.6% | |
| Total wages/salary | Rs m | 3,765 | 17,678 | 21.3% | |
| Avg. sales/employee | Rs Th | 3,128.4 | 10,667.8 | 29.3% | |
| Avg. wages/employee | Rs Th | 554.0 | 1,264.3 | 43.8% | |
| Avg. net profit/employee | Rs Th | 689.7 | 1,645.8 | 41.9% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 21,258 | 149,157 | 14.3% | |
| Other income | Rs m | 242 | 1,159 | 20.8% | |
| Total revenues | Rs m | 21,499 | 150,316 | 14.3% | |
| Gross profit | Rs m | 6,584 | 34,343 | 19.2% | |
| Depreciation | Rs m | 596 | 4,276 | 13.9% | |
| Interest | Rs m | 4 | 667 | 0.6% | |
| Profit before tax | Rs m | 6,226 | 30,558 | 20.4% | |
| Minority Interest | Rs m | 0 | 50 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 1,539 | 7,597 | 20.3% | |
| Profit after tax | Rs m | 4,686 | 23,012 | 20.4% | |
| Gross profit margin | % | 31.0 | 23.0 | 134.5% | |
| Effective tax rate | % | 24.7 | 24.9 | 99.5% | |
| Net profit margin | % | 22.0 | 15.4 | 142.9% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 12,236 | 92,062 | 13.3% | |
| Current liabilities | Rs m | 3,461 | 66,223 | 5.2% | |
| Net working cap to sales | % | 41.3 | 17.3 | 238.3% | |
| Current ratio | x | 3.5 | 1.4 | 254.4% | |
| Inventory Days | Days | 60 | 106 | 56.8% | |
| Debtors Days | Days | 84 | 68 | 124.8% | |
| Net fixed assets | Rs m | 11,140 | 62,919 | 17.7% | |
| Share capital | Rs m | 177 | 586 | 30.2% | |
| "Free" reserves | Rs m | 20,237 | 93,133 | 21.7% | |
| Net worth | Rs m | 20,414 | 93,719 | 21.8% | |
| Long term debt | Rs m | 10 | 1,814 | 0.6% | |
| Total assets | Rs m | 24,486 | 162,494 | 15.1% | |
| Interest coverage | x | 1,519.4 | 46.8 | 3,246.6% | |
| Debt to equity ratio | x | 0 | 0 | 2.6% | |
| Sales to assets ratio | x | 0.9 | 0.9 | 94.6% | |
| Return on assets | % | 19.2 | 14.6 | 131.5% | |
| Return on equity | % | 23.0 | 24.6 | 93.5% | |
| Return on capital | % | 30.5 | 32.7 | 93.2% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 11,667 | 75,838 | 15.4% | |
| Fx outflow | Rs m | 1,616 | 30,224 | 5.3% | |
| Net fx | Rs m | 10,052 | 45,613 | 22.0% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 2,854 | 32,786 | 8.7% | |
| From Investments | Rs m | -2,604 | -17,870 | 14.6% | |
| From Financial Activity | Rs m | -2 | -19,153 | 0.0% | |
| Net Cashflow | Rs m | 248 | -4,239 | -5.9% | |
Share Holding
| Indian Promoters | % | 73.8 | 54.1 | 136.4% | |
| Foreign collaborators | % | 0.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 1.6 | 8.0 | 19.5% | |
| FIIs | % | 7.6 | 27.7 | 27.4% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 17.0 | 10.2 | 166.7% | |
| Shareholders | 20,968 | 69,601 | 30.1% | ||
| Pledged promoter(s) holding | % | 4.4 | 8.6 | 51.3% |
Compare AJANTA PHARMA With: SUN PHARMA DR. REDDYS LAB GSK PHARMA FULFORD INDIA MERCK LTD
Compare AJANTA PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)
After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.
Related Views on News
AUROBINDO PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 12.0% (Quarterly Result Update)
Aug 13, 2018 | Updated on Aug 13, 2018For the quarter ended June 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 12.0% YoY). Sales on the other hand came in at Rs 43 bn (up 15.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
AJANTA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 11.6% (Quarterly Result Update)
Aug 1, 2018 | Updated on Aug 1, 2018For the quarter ended June 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 11.6% YoY). Sales on the other hand came in at Rs 5 bn (up 8.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
More Views on NewsMost Popular
In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)
Sep 6, 2018The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?
As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)
Sep 5, 2018Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?
Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)
Sep 5, 2018The tax collected has gone up a little but the question is at what cost.
The Cream of Small Cap Stocks(Profit Hunter)
Sep 5, 2018Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.
The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)
Sep 7, 2018The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.
More|
| |
AJANTA PHARMA SHARE PRICE
Sep 18, 2018 (Close)
TRACK AJANTA PHARMA
- Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON AJANTA PHARMA
AJANTA PHARMA 8-QTR ANALYSIS
COMPARE AJANTA PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.